| 53.57 -0.115 (-0.21%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 66.01 | 1-year : | 77.1 |
| Resists | First : | 56.52 | Second : | 66.01 |
| Pivot price | 53.73 |
|||
| Supports | First : | 49.63 | Second : | 45.38 |
| MAs | MA(5) : | 53.26 |
MA(20) : | 52.79 |
| MA(100) : | 51.64 |
MA(250) : | 53.52 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 41.5 |
D(3) : | 47.1 |
| RSI | RSI(14): 58.7 |
|||
| 52-week | High : | 72.83 | Low : | 38.81 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ EXAS ] has closed above bottom band by 45.8%. Bollinger Bands are 53% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 54.13 - 54.42 | 54.42 - 54.66 |
| Low: | 52.33 - 52.66 | 52.66 - 52.93 |
| Close: | 53.04 - 53.59 | 53.59 - 54.06 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Sat, 27 Sep 2025
Exact Sciences Corporation $EXAS Shares Sold by Park Avenue Securities LLC - MarketBeat
Thu, 25 Sep 2025
Exact Sciences (EXAS) Stock Trades Up, Here Is Why - Yahoo
Thu, 25 Sep 2025
Exact Sciences' Clear Expansion Path: Why Choose To Buy (NASDAQ:EXAS) - Seeking Alpha
Wed, 24 Sep 2025
25,000 Shares in Exact Sciences Corporation $EXAS Acquired by Waycross Partners LLC - MarketBeat
Tue, 23 Sep 2025
Pallas Capital Advisors LLC Boosts Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Mon, 22 Sep 2025
Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 189 (M) |
| Shares Float | 187 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 95.6 (%) |
| Shares Short | 7,340 (K) |
| Shares Short P.Month | 6,880 (K) |
| EPS | -5.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.05 |
| Profit Margin | -34.2 % |
| Operating Margin | 0.3 % |
| Return on Assets (ttm) | -1.4 % |
| Return on Equity (ttm) | -35.6 % |
| Qtrly Rev. Growth | 16 % |
| Gross Profit (p.s.) | 10.82 |
| Sales Per Share | 15.52 |
| EBITDA (p.s.) | 0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 306 (M) |
| Levered Free Cash Flow | 140 (M) |
| PE Ratio | -9.83 |
| PEG Ratio | 0 |
| Price to Book value | 4.1 |
| Price to Sales | 3.44 |
| Price to Cash Flow | 33.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|